| Bioactivity | JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy[1]. |
| Target | IC50: 1.6 μM (Skeletal muscle myosin), 5.4 μM (Cardiac muscle myosin), and >100 μM (Smooth muscle myosin II) |
| Invitro | JB062 (compound 6b; 40 μM; 24 h) 抑制 COS-7 细胞的胞质分裂[1]。JB062 (COS-7 细胞) 对人类癌细胞具有细胞毒性，但对正常细胞没有细胞毒性，CC10 值为 36 μM[1]。 |
| Name | JB062 |
| CAS | 2417988-00-0 |
| Formula | C19H17NO4 |
| Molar Mass | 323.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Smith JD, et, al. Isoform selectivities of novel 4-hydroxycoumarin imines as inhibitors of myosin II. Eur J Med Chem. 2022 Dec 12;247:115008. |